Search tips
Search criteria 


Logo of hsresearchLink to Publisher's site
Health Serv Res. 1999 February; 33(6): 1593–1610.
PMCID: PMC1070338

Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?


OBJECTIVE: To examine the impact of a policy restricting reimbursement for Medicaid anti-ulcer drugs on anti-ulcer drug use and peptic-related hospitalizations. DATA SOURCES/STUDY SETTING: In addition to U.S. Census Bureau data, all of the following from Florida: Medicaid anti-ulcer drug claims data, 1989-1993; Medicaid eligibility data, 1989-1993; and acute care nonfederal hospital discharge abstract data (Medicaid and non-Medicaid), 1989-1993. STUDY DESIGN: In this observational study, a Poisson multiple regression model was used to compare changes, after policy implementation, in Medicaid reimbursement for prescription anti-ulcer drugs as well as hospitalization rates between pre- and post-implementation periods in Medicaid versus non-Medicaid patients hospitalized with peptic ulcer disease. PRINCIPAL FINDINGS: Following policy implementation, the rate of Medicaid reimbursement for anti-ulcer drugs decreased 33 percent (p < .001). No associated increase occurred in the rate of Medicaid peptic-related hospitalizations. CONCLUSIONS: Florida's policy restricting Medicaid reimbursement for anti-ulcer drugs was associated with a substantial reduction in outpatient anti-ulcer drug utilization without any significant increase in the rate of hospitalization for peptic-related conditions.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Berstad A, Weberg R. Antacids for peptic ulcer: do we have anything better? Scand J Gastroenterol Suppl. 1986;125:32–41. [PubMed]
  • Brown CM, Lipowski EE. Pharmacists' reactions to the Wisconsin Medicaid drug-use review program. Am J Hosp Pharm. 1993 Sep;50(9):1898–1902. [PubMed]
  • Christensen A, Bousfield R, Christiansen J. Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists. Ann Surg. 1988 Jan;207(1):4–6. [PubMed]
  • Gudmand-Høyer E, Jensen KB, Krag E, Rask-Madsen J, Rahbek I, Rune SJ, Wulff HR. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J. 1978 Apr 29;1(6120):1095–1097. [PMC free article] [PubMed]
  • Hunter JO, Walker RJ, Crowe J, Gillies RR, Gillies KR, Gough KR, Lorber S. Double-blind randomized multicenter study comparing Maalox TC tablets and ranitidine in healing of duodenal ulcers. Dig Dis Sci. 1991 Jul;36(7):911–916. [PubMed]
  • McKay AJ, McArdle CS. Cimetidine and perforated peptic ulcer. Br J Surg. 1982 Jun;69(6):319–320. [PubMed]
  • Paimela H, Tuompo PK, Peräkyl T, Saario I, Höckerstedt K, Kivilaakso E. Peptic ulcer surgery during the H2-receptor antagonist era: a population-based epidemiological study of ulcer surgery in Helsinki from 1972 to 1987. Br J Surg. 1991 Jan;78(1):28–31. [PubMed]
  • Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q. 1993;71(2):217–252. [PubMed]
  • Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T j, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991 Oct 10;325(15):1072–1077. [PubMed]
  • Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987 Aug 27;317(9):550–556. [PubMed]
  • Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994 Sep 8;331(10):650–655. [PubMed]
  • Zimmerman DR, Collins TM, Lipowski EE, Sainfort F. Evaluation of a DUR intervention: a case study of histamine antagonists. Inquiry. 1994 Spring;31(1):89–101. [PubMed]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust